S tier · elite
For its approved indication — relief and prevention of bronchospasm — salbutamol is among the best-evidenced drugs in medicine, with decades of randomised trials, an FDA-approved label and global essential-medicine status.
salbutamol
Salbutamol is a short-acting beta-2 agonist approved for the treatment and prevention of bronchospasm in reversible obstructive airway disease and for prevention of exercise-induced bronchospasm. Its efficacy for these respiratory indications is established across a very large randomised and regulatory evidence base.
the explanation
Salbutamol is the blue rescue inhaler used for asthma. It opens up narrowed airways within minutes, and the evidence that it does this is about as strong as evidence in medicine gets.
regulatory status
FDA-approved (respiratory indications)
Approved in patients 4 years and older for the treatment or prevention of bronchospasm in reversible obstructive airway disease and for prevention of exercise-induced bronchospasm. Widely licensed internationally. Restricted in competitive sport above defined inhaled thresholds.
how it works · proposed mechanism
Salbutamol is a selective agonist at the beta-2 adrenoceptor on airway smooth muscle.
Airway smooth muscle relaxation
Beta-2 receptor binding activates adenylyl cyclase, raising cyclic AMP and lowering intracellular calcium in bronchial smooth muscle. The result is rapid bronchodilation, typically within minutes of inhalation.
Short-acting kinetics
Salbutamol has a short duration relative to long-acting beta-agonists, with an effective half-life of about 5 hours. This makes it a rescue rather than a controller therapy, and rising need for it is a recognised marker of deteriorating asthma control.
Systemic beta-2 spillover
Beta-2 receptors on skeletal muscle, cardiac tissue and the Na+/K+-ATPase are also engaged, producing tremor, tachycardia and intracellular potassium shifting. These same systemic effects underlie both its labelled cardiovascular warnings and its interest as a repartitioning agent.
what’s reported
evidence shape
6 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
Salbutamol's S grade is for asthma and bronchospasm, not for physique change — the randomised body-composition data are small, sex-dependent and modest, with a controlled trial finding a fat mass reduction only in trained females and no significant effect in males. Grading the respiratory evidence highly says nothing about whether it works as a fat-loss agent, and the label's warnings about excessive use of inhaled sympathomimetics apply with full force to non-respiratory use.
key published findings
- Human trial (randomised, controlled): Hostrup and colleagues randomised 40 well-trained participants (19 females, 21 males) during endurance training; only salbutamol-treated females showed fat mass reduction versus placebo (-0.8 kg at 6 weeks; 95% CI -0.5 to -1.6; p=0.039), with a sex-by-treatment interaction of p=0.048.
- Human trial (same study): salbutamol-treated females showed a repartitioning effect, losing fat mass while gaining lean mass (p=0.011), an effect not apparent in males (p=0.303).
- Human trial (randomised, controlled): a subsequent trial reported lean mass gains alongside cardiac remodelling and muscle oxidative changes with high-dose salbutamol during resistance training, indicating that any anabolic signal is accompanied by structural cardiac change.
- Human trial: a randomised study reported that the anabolic effects of salbutamol are lost upon immobilisation, implying dependence on concurrent loading rather than a standalone effect.
- Regulatory (label): the FDA-approved label states that salbutamol 'may produce significant hypokalaemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects.'
limitations of the evidence
- Body-composition trials are small (tens of participants), short (around 6 weeks) and conducted in already well-trained volunteers, so effect sizes may not generalise.
- The fat mass effect was detected in females only and did not reach significance in males, so the finding is not robustly generalisable across sexes.
- Trials using systemically meaningful exposures report concurrent cardiac remodelling, meaning the anabolic and cardiac signals cannot be cleanly separated in the existing data.
documented safety signals
- Paradoxical bronchospasm that may be life-threatening is a labelled warning; the label instructs immediate discontinuation if it occurs.
- The label warns that 'fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma.'
- Clinically significant cardiovascular effects measurable as pulse rate and blood pressure changes are labelled, with caution advised in patients with cardiac disorders.
- Significant hypokalaemia via intracellular potassium shunting is labelled, with potential for adverse cardiovascular effects.
- Increasing need for rescue doses is a labelled marker of destabilising asthma and requires clinical re-evaluation rather than escalation.
- Tremor, palpitations, nervousness and headache are common beta-2 class effects.
- Randomised data using higher systemic exposures document cardiac remodelling, a structural change of uncertain long-term significance in non-asthmatic users.
- Immediate hypersensitivity reactions and, with beta-agonist class agents, QT interval and metabolic effects are recognised.
- Restricted above defined thresholds in competitive sport, so non-medical use carries anti-doping consequences.
identity
| full name | Salbutamol sulfate (albuterol sulfate) |
| category | Thyroid & Stimulant |
| modality | small molecule |
| formula | C13H21NO3 |
| molar mass | 239.31 g/mol |
| cas | 18559-94-9 |
| half-life | ~5 h (inhaled, effective half-life) |
laboratory handling
| storage | Marketed inhalers and tablets are stored at controlled room temperature per the approved label; pressurised metered-dose canisters carry additional warnings against puncturing or incinerating and against exposure to high temperature. |
| solubility | Salbutamol sulfate is a water-soluble salt; the free base is appreciably less water-soluble, which is why marketed formulations use the sulfate. |
| co-studied with | The label notes additive cardiovascular effects with other sympathomimetics and cautions on concurrent non-potassium-sparing diuretics because of compounded hypokalaemia; monoamine oxidase inhibitors and tricyclic antidepressants are flagged for potentiation of cardiovascular effects. Recorded as documented interactions, not a regimen. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
6 citedDailyMed / US FDA · 2023 · official
ERJ Open Research · 2023 · randomized
Scandinavian Journal of Medicine & Science in Sports · 2026 · randomized
Journal of Cachexia, Sarcopenia and Muscle · 2025 · randomized
Journal of Strength and Conditioning Research · 2005 · randomized
Journal of Applied Physiology · 2000 · randomized
others in Thyroid & Stimulant